SwishX pivots to AI to streamline pharmaceutical sales and operations

Indian tech company SwishX has pivoted from enterprise device procurement to an AI-powered platform targeting the pharmaceutical and medtech industries. The company aims to streamline sales, distribution, hospital contracting, and government tender processes for drugmakers.

Originally launched as Swish Club offering IT asset leasing, founders Dushyant Sapre, Suraj Kumar, and Jai Anand identified a need for a more specialized business. They shut down the original offering, rebranded as SwishX, and developed an agentic AI platform focusing on deeply specialized, industry-specific workflows. This strategy contrasts with the broader market trend of developing general AI copilots.

SwishX claims to have already achieved over $1 million in annual recurring revenue (ARR) and serves several of India's largest pharmaceutical companies. The company projects reaching $5 million in contracted ARR and acquiring over 100 enterprise clients by the end of fiscal year 2027.

The pharmaceutical industry in India, valued at over $65 billion, often relies on fragmented systems and legacy software for critical commercial operations. SwishX addresses this gap with four AI products: Tender IQ for managing tender submissions, Contract IQ for automating hospital contract negotiations, Marketing IQ for converting marketing materials into short-form video, and Channel IQ for improving distributor engagement. These tools are designed to enhance commercial execution and efficiency.